First Drug for Deadly Transplant Complication Gets FDA’s Blessing

(MedPage Today) — The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA) in adults and kids ages 2 years and up, said maker Omeros on Wednesday…